Wall Street analysts expect Liquidia Co. (NASDAQ:LQDA – Get Rating) to report sales of $3.26 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts provided Liquidia earnings estimates. The lowest sales estimate is $3.10 million and the highest is $3.50 million. Liquidia posted sales of $3.08 million in the same quarter last year, suggesting a positive year-over-year growth rate of 5.8%. The company is due to release its next earnings report on Monday, January 1.
On average, analysts expect Liquidia to post annual revenue of $16.61 million for the current fiscal year, with estimates ranging from $13.03 million to $22.80 million. dollars. For next year, analysts expect the company to record sales of $52.90 million, with estimates ranging from $27.80 million to $90.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts who cover Liquidia.
Liquidia (NASDAQ:LQDA – Get Rating) last released its quarterly results on Thursday, March 17. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.11) by ($0.12). The company posted revenue of $3.22 million in the quarter, versus a consensus estimate of $2.89 million. In the same quarter of the previous year, the company had made earnings per share ($0.38).
A number of equity research analysts have published reports on the company. HC Wainwright raised its price target on Liquidia from $6.00 to $16.00 and gave the company a “buy” rating in a Thursday, Feb. 3 research report. Wedbush reaffirmed a “hold” rating and issued a $6.00 price target on Liquidia shares in a research report on Friday, January 7. Needham & Company LLC raised its price target on Liquidia from $8.00 to $12.00 and gave the company a “buy” rating in a Monday, January 10 research report. Finally, Zacks Investment Research downgraded Liquidia from a “hold” rating to a “sell” rating in a Wednesday, April 6 research report.
In other news, Director Caligan Partners Lp purchased 1,764,705 shares of the company in a transaction on Monday April 18. The shares were purchased at an average price of $5.10 per share, with a total value of $8,999,995.50. Following completion of the transaction, the administrator now directly owns 10,093,123 shares of the company, valued at approximately $51,474,927.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this link. Insiders hold 29.50% of the shares of the company.
Several hedge funds have recently changed their positions in LQDA. Eversept Partners LP increased its stake in Liquidia shares by 55.8% in the 4th quarter. Eversept Partners LP now owns 1,447,898 shares of the company valued at $7,051,000 after purchasing an additional 518,849 shares in the last quarter. Harbert Fund Advisors Inc. increased its stake in Liquidia shares by 840.2% in the third quarter. Harbert Fund Advisors Inc. now owns 420,939 shares of the company valued at $1,162,000 after purchasing an additional 376,168 shares in the last quarter. Morgan Stanley increased its stake in Liquidia shares by 337.6% in the second quarter. Morgan Stanley now owns 388,312 shares of the company valued at $1,111,000 after buying an additional 299,571 shares in the last quarter. Soleus Capital Management LP purchased a new equity stake in Liquidia in the fourth quarter valued at approximately $1,127,000. Finally, DE Shaw & Co. Inc. increased its equity stake in Liquidia by 113.9% in the fourth quarter. DE Shaw & Co. Inc. now owns 368,849 shares of the company valued at $1,796,000 after purchasing an additional 196,430 shares last quarter. Institutional investors hold 33.61% of the company’s shares.
LQDA stock opened at $5.63 on Monday. The company has a market capitalization of $362.26 million, a P/E ratio of -7.93 and a beta of 0.13. The company’s 50-day moving average is $6.44 and its two-hundred-day moving average is $5.30. Liquidia has a 1-year low of $2.25 and a 1-year high of $7.78.
Liquidia company profile (Get an assessment)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures and markets various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
Get a Free Copy of Zacks Research Report on Liquidia (LQDA)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Receive news and reviews for Liquidia Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst notes for Liquidia and related companies with MarketBeat.com’s free daily email newsletter.